Products Affected - Description

• • IFEX powder for solution for injection, Baxter, 1 gram, vial, 1 count, NDC 00338-3991-01
  • IFEX powder for solution for injection, Baxter, 3 gram, vial, 1 count, NDC 00338-3993-01
  • Ifosfamide powder for solution for injection, Baxter, 1 gram, vial, 1 count, NDC 10019-0925-01
  • Ifosfamide powder for solution for injection, Baxter, 3 gram, vial, 1 count, NDC 10019-0926-02
  • Ifosfamide lyophilized powder for injection, Fresenius Kabi, 1 gram, vial, 1 count, NDC 63323-0142-10
  • Ifosfamide injection, Hikma, 50 mg/mL, 20 mL vial, NDC 00143-9531-01
  • Ifosfamide injection, Hikma, 50 mg/mL, 60 mL vial, NDC 00143-9530-01

Reason for the Shortage

• • Baxter has ifosfamide injection on shortage due to manufacturing delays.
  • Fresenius Kabi has ifosfamide injection on shortage due to increased demand.
  • Hikma has ifosfamide injection on shortage due to increased demand.

Available Products

• • There are no presentations available

• • Fresenius Kabi has ifosfamide 1 gram vials on back order and the company estimates a release date of mid- to late-August 2026.
  • Hikma has ifosfamide 50 mg/mL 20 mL vials and 60 mL vials on back order and the company estimates a release date of late-September to early-October 2026.
  • Baxter has 1 gram vials and 3 gram vials on back order and the company estimates a release date of early-September 2026 for the 1 gram vials and late-August 2026 for the 3 gram vials.
  • Baxter has IFEX 1 gram on back order and the company cannot estimate a release date. The 3 gram vials are on back order and the company estimates a release date of October 2026.

• • ASPR TRACIE has worked with key subject matter experts to develop clinical resources for emergency shortages of treatments and supplies (CRESTS). Information for ifosfamide is available at Clinical Resources for Emergency Shortages of Treatments and Supplies | ASPR TRACIE: https://files.asprtracie.hhs.gov/documents/crests-ifosfamide-shortage-considerations.pdf

• • Tertiary references show ifosfamide is chemically stable at room temperature and in the refrigerator for extended periods of time. Organizations should review their current operations to determine if these stability data can help stretch limited supplies of ifosfamide.[1-2]

• • Consider evaluating the health-care system's total supply of ifosfamide before beginning patients on combination chemotherapy regimens containing ifosfamide. If adequate supplies are not available, select an alternative regimen.
  • The choice of an alternative agent must be patient-specific and based on renal function, liver function, and the neoplasm type and location. No single agent can be substituted for ifosfamide.
  • Consult a Hematology/Oncology specialist for patient- and neoplasm-specific recommendations.
  • Refer to the ASHP Guidelines on Managing Drug Product Shortages for more guidance on developing a multidisciplinary plan when the supply must be allocated. https://www.ashp.org/-/media/assets/policy-guidelines/docs/guidelines/managing-drug-product-shortages.pdf
  • Refer to national guidelines such as those from the National Comprehensive Cancer Network (www.nccn.org) or American Society of Clinical Oncology (http://www.asco.org/) for additional information regarding therapeutic use.

• 1. Simpson MC. Schaefer EG. Ifosfamide. Extended Stability for Parenteral Drugs, 7th Edition. American Society of Health-System Pharmacists; 2023:227-228.
  2. Ifosfamide. King Guide to Parenteral Admixtures, Internet Edition, Napa, California: King Guide Publications, Inc.; 2026; July 8, 2026.